Pharmaceutical Technology
NOVEMBER 4, 2023
QL-325 is under clinical development by QLSF Biotherapeutics and currently in Phase I for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia).
Pharmacy Times
NOVEMBER 4, 2023
Leung discusses that various cancer types and drugs can cause thrombotic microangiopathy and impact kidney health and the renal complications connected to hematologic malignancies.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Pharmaceutical Technology
NOVEMBER 4, 2023
MBX-1416 is under clinical development by MBX Biosciences Inc and currently in Phase II for Hypoglycemia.
Pharmacy Times
NOVEMBER 4, 2023
Understanding the mechanisms leading to weight loss could help identify potential benefits for cardiorenal health in patients with chronic kidney disease.
Advertisement
What if you could help your sellers stop wasting 72% of their day on non-selling activities and focus on bringing in revenue? Incorporating AI in your enablement workflows can help you cut down on busy work, get projects done faster, and let your team (and you!) focus on making a bigger impact. We put together this guide to show you how to use AI to cut time and costs for projects, including collateral creation, development of training videos, and automating tedious processes.
Pharmaceutical Technology
NOVEMBER 4, 2023
D3L-001 is under clinical development by D3 Bio and currently in Phase I for Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer (HER2+ Breast Cancer).
Pharmacy Times
NOVEMBER 4, 2023
Awdishu describes the implementation of new equations to accurately drug dose in patients as well as provide updated guidance on the dosing of older medications.
Pharma Rep Focus brings together the best content for pharma rep professionals from the widest variety of industry thought leaders.
Pharmacy Times
NOVEMBER 4, 2023
Exercise has the potential to improve physical performance and fitness at the very least, but a multidisciplinary intervention may work better for patients with chronic kidney disease.
Pharmaceutical Technology
NOVEMBER 4, 2023
Debio-4127 is under clinical development by Debiopharm International and currently in Phase II for Neuroendocrine Gastroenteropancreatic Tumors (GEP-NET).
Pharmacy Times
NOVEMBER 4, 2023
Sodium-glucose cotransporter-2 inhibitors and sodium zirconium cyclosilicate may be paired with these kidney disease medications to reduce high serum potassium.
Pharmaceutical Technology
NOVEMBER 4, 2023
Debio-4127 is under clinical development by Debiopharm International and currently in Phase II for Neuroendocrine Gastroenteropancreatic Tumors (GEP-NET).
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
Pharmaceutical Technology
NOVEMBER 4, 2023
QL-325 is under clinical development by QLSF Biotherapeutics and currently in Phase I for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia).
Pharmaceutical Technology
NOVEMBER 4, 2023
D3L-001 is under clinical development by D3 Bio and currently in Phase I for Gastroesophageal (GE) Junction Carcinomas.
Pharmaceutical Technology
NOVEMBER 4, 2023
D3L-001 is under clinical development by D3 Bio and currently in Phase I for Gastroesophageal (GE) Junction Carcinomas.
Pharmaceutical Technology
NOVEMBER 4, 2023
HUC-3443 is under clinical development by Huons and currently in Phase II for Idiopathic (Essential) Hypertension.
Advertisement
Every marketer knows how important it is to prove their efforts drive sales opportunities, but that’s easier said than done. When problems like sales and marketing misalignment, lack of data, and wasted efforts persist, marketers can’t measure, prove, or increase their impact on revenue at a time when demonstrating marketing value is critical. Using analyst and expert data, this guide to marketing impact and content attribution explains: How B2B buyers use content The most common types of conten
Pharmaceutical Technology
NOVEMBER 4, 2023
HUC-3443 is under clinical development by Huons and currently in Phase II for Idiopathic (Essential) Hypertension.
Pharmaceutical Technology
NOVEMBER 4, 2023
RPA-601 is under clinical development by Rocket Pharmaceuticals and currently in Phase I for Cardiomyopathy.
Pharmaceutical Technology
NOVEMBER 4, 2023
RPA-601 is under clinical development by Rocket Pharmaceuticals and currently in Phase I for Cardiomyopathy.
Pharmaceutical Technology
NOVEMBER 4, 2023
MBX-1416 is under clinical development by MBX Biosciences Inc and currently in Phase II for Hypoglycemia.
Pharmaceutical Technology
NOVEMBER 4, 2023
Melpida is under clinical development by Elpida Therapeutics and currently in Phase II for Paraplegia.
Pharmaceutical Technology
NOVEMBER 4, 2023
PHIN-214 is under clinical development by PharmaIN and currently in Phase I for Portal Hypertension.
Pharmaceutical Technology
NOVEMBER 4, 2023
PHIN-214 is under clinical development by PharmaIN and currently in Phase I for Portal Hypertension.
Pharmaceutical Technology
NOVEMBER 4, 2023
HUC-3443 is under clinical development by Huons and currently in Phase II for Hypercholesterolemia.
Advertisement
Quotas need to be hit. Revenue goals need to be met. This reality makes shortening sales onboarding time a top priority. Organizations with a standard onboarding process boost employee retention by 58% and increase productivity by 50%. Unfortunately, many companies struggle with inefficient processes that lead to high turnover and missed revenue opportunities.
Pharmaceutical Technology
NOVEMBER 4, 2023
HUC-3443 is under clinical development by Huons and currently in Phase II for Hypercholesterolemia.
Expert insights. Personalized for you.
52 
Let's personalize your content